Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-501 and Rimiducid for GVHD Prevention in Non-Malignant Diseases
NCT02231710Phase 1Terminated
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Feb 2015
- Primary completion
- Sep 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rivogenlecleucel in primary immunodeficiency disorder (PID), hemophagocytic lymphohistiocytosis (HLH), inherited bone marrow failure syndrome (IBMFS) and 3 more, sponsored by Bellicum Pharmaceuticals, Inc. Primary endpoints: Adverse Events at 24 months and Engraftment at Day 28. Started Feb 2015; status: terminated.
02
Drugs
rivogenlecleucel
03
Conditions
primary immunodeficiency disorder (PID)hemophagocytic lymphohistiocytosis (HLH)inherited bone marrow failure syndrome (IBMFS)hemoglobinopathymetabolic disorder
Beyond the preview
Go deeper on NCT02231710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231710.